How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/metastatic-breast-cancer-progression-post-antiestrogen-therapy.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Metastatic Breast Cancer Progression Post-Antiestrogen Therapy — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metastatic Breast Cancer Progression Post-Antiestrogen Therapy (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Metastatic Breast Cancer Progression Post-Antiestrogen Therapy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Faslodex	fulvestrant	AstraZeneca	Estrogen Receptor Antagonist [EPC]	Progesterone receptor		2002-01-01
Faslodex	Faslodex	Translational Oncology Research International		NAD-dependent protein deacylase sirtuin-5, mitochondrial, Bifunctional epoxide hydrolase 2, G-protein coupled estrogen receptor 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AstraZeneca · 1 drug in Metastatic Breast Cancer Progression Post-Antiestrogen Therapy
Translational Oncology Research International · 1 drug in Metastatic Breast Cancer Progression Post-Antiestrogen Therapy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Metastatic Breast Cancer Progression Post-Antiestrogen Therapy:

Cite this brief

Drug Landscape (2026). Metastatic Breast Cancer Progression Post-Antiestrogen Therapy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/metastatic-breast-cancer-progression-post-antiestrogen-therapy. Accessed 2026-06-10.

Metastatic Breast Cancer Progression Post-Antiestrogen Therapy full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing